AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04238195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Description: Treatment C: Subjects receive TBPM-PI-HBr matching placebo.
Study NCT04238195 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Description: Treatment C: Subjects receive TBPM-PI-HBr matching placebo.
Study NCT04238195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Description: Treatment B: Subjects receive TBPM-PI-HBr.
Study NCT03280615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
Study NCT03280615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: Corn oil will be the placebo comparator for omega 3 fatty acids supplement
Study NCT03052257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational - glaucoma
Description: Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
Study NCT03052257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dose monitoring and reminder
Description: Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated.
Study NCT03052257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational - general
Description: The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
Study NCT03052257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose monitoring
Description: Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened.
Study NCT03550326 — intervention group
Intervention type: PROCEDURE
Intervention: airway management
Description: patients will be intubated or will be placed an airway device
Study NCT01615003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuesaitong soft capsule
Description: Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
Study NCT01615003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xuesaitong soft capsule Placebo
Description: Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
Study NCT04499508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optima Coil System
Description: Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
Study NCT02821793 — intervention group
Intervention type: OTHER
Intervention: Consultation, evaluation questionnaire
Description: Consultation, evaluation questionnaire
Study NCT02821793 — intervention group
Intervention type: OTHER
Intervention: Geriatric consultation, evaluation questionnaire
Description: Geriatric consultation, evaluation questionnaire
Study NCT04288076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP Titrated Mechanical Ventilation
Description: Subjects will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O and back down to 5 cmH20. Pleural pressure and intracranial pressure will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set > 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. At the completion of the study patients will be returned to the PEEP level they were on prior to titration of the ventilator.
Study NCT00286533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination (implant stability, gingiva condition, etc.)
Description: Clinical examination (implant stability, gingiva condition, etc.) to follow
Study NCT00286533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires are used.
Study NCT04152356 — intervention group
Intervention type: DRUG
Intervention: PD-1
Description: PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
Study NCT04152356 — intervention group
Intervention type: DRUG
Intervention: Sorafenib
Description: Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
Study NCT01595256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: muscular strength
Description: 12-week moderate intensity walking program
Study NCT03699839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine
Description: The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
Study NCT03699839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine
Description: The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
Study NCT03699839 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intramuscular influenza vaccine
Description: The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
Study NCT03137394 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.
Study NCT03061968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure
Description: The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
Study NCT02145767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Study NCT02145767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03465852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChiCAS
Description: Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
Study NCT03465852 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ChiCAS
Description: Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
Study NCT02692053 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sampling
Description: additional blood sampling (volume: 18 mL)
Study NCT02692053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: additional blood sampling (volume: 18 mL)
Study NCT01220752 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion boost
Description: 8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
Study NCT02143518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel®
Description: The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
Study NCT02143518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG 10104
Description: Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
Study NCT01198444 — intervention group
Intervention type: DRUG
Intervention: EE/DRSP (Yasmin Product Family)
Description: One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
Study NCT03692910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 capsule
Study NCT03692910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matching placebo capsule
Study NCT03611400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10\^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10\^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
Study NCT03611400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
Study NCT00509873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.5% eye drops
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Study NCT00509873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Study NCT00193674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: 20 mg/day, oral
Study NCT00193674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01883245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: 2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
Study NCT01883245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS
Description: 2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
Study NCT03253198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
Study NCT03253198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine liposome
Description: an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
Study NCT01583582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marealis Refined Peptide Concentrate
Description: 1200 mg per os, once a day, 8 weeks
Study NCT01583582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marealis Refined Peptide Concentrate
Description: 600 mg per os, twice a day, 8 weeks
Study NCT01583582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Marealis Refined Peptide Concentrate
Description: 0 mg per os, daily, 8 weeks
Study NCT04066556 — intervention group
Intervention type: OTHER
Intervention: Brain CT imaging
Description: The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~* Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~* Cut-off values in areas of irreversible changes according to non-contrast CT images~* Cut-off values in occlusion sites and collateral scores according to CT angiographies~* Cut-off values of consolidated CT imaging index including clot, core, and collateral score~* Cut-off values of comorbidity index~* Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments.
Study NCT01914445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo Carmine
Description: Oral administration of Indigo Carmine prior to colonoscopy
Study NCT02538666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02538666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02538666 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01651182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No tranexamic acid
Description: Control
Study NCT01651182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT00687154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scatter Laser Photocoagulation in 1 Sitting
Description: 1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
Study NCT00687154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scatter Laser Photocoagulation in 4 Sittings
Description: 4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
Study NCT02844582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV
Study NCT02844582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02416908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Study NCT02416908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Study NCT02369679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precast Adjustable Compression Wrap (Circaid)
Description: A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days).
Study NCT02416908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT02416908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02416908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy
Study NCT01807507 — intervention group
Intervention type: DEVICE
Intervention: VeinViewer
Description: VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
Study NCT00959296 — intervention group
Intervention type: DEVICE
Intervention: Various
Description: Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
Study NCT00763685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etoricoxib
Description: etoricoxib 120 mg, paracetamol 1 g
Study NCT00763685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: etoricoxib 120 mg, paracetamol 1 g
Study NCT00298610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous Artesunate (2.4 mg/kg) once a day for three days
Study NCT00298610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone
Description: (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
Study NCT03566537 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Thyroidectomy
Study NCT01585129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postpartum Antibiotics
Description: Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
Study NCT01585129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No postpartum antibiotics
Description: Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
Study NCT03614429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel will be prepared according to an international product Instillagel®
Description: Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol\* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not.
Study NCT02369679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multilayer Compression Bandages
Description: A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days).
Study NCT00558480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months